The survival benefit of axitinib when combined with pembrolizumab in metastatic sarcomas showed in the NCT02636725 study [38] could not be explained by the high percentage of PD-L1+ tumor cells nor by the high TIL scores. This evidence concerns the gene CD274 and sarcoma.